Bipolar Disorder
📧 Sign up to get email alerts when something new happens for Bipolar Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2008-12-19Clinical Trial Update: Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study [Phase 4]
Phase 4 clinical trial evaluating valproate (Depakine Chrono) for mania in bipolar disorder in the Gulf region has completed.
-
CLINICAL_TRIALS trial_result · 2008-12-11Clinical Trial Update: Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI) [Phase 4]
This clinical trial update reports the completion of a Phase 4 study evaluating injectable naltrexone for alcohol dependence in individuals …
-
CLINICAL_TRIALS research · 2008-12-03Clinical Trial Update: Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers
A completed clinical trial explored subjective well-being in bipolar disorder patients treated with atypical antipsychotics as monotherapy o…
-
FDA approval · 2008-11-25FDA Approved: DIVALPROEX SODIUM — Original Application (Bionpharma Inc.)
FDA approved Bionpharma's original application for divalproex sodium, making a generic version available for epilepsy, bipolar disorder, and…
-
FDA approval · 2008-11-25FDA Approved: HALOPERIDOL — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for HALOPERIDOL (generic) from PAI Holdings, LLC dba PAI Pharma under ANDA073037.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2008-11-19FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for chlorpromazine hydrochloride (Upsher-Smith Laboratories, LLC).
-
FDA approval · 2008-11-19FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved a supplemental application for chlorpromazine hydrochloride from Upsher-Smith Laboratories, approving changes to the approved d…
-
FDA approval · 2008-11-19FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for chlorpromazine hydrochloride from Upsher-Smith Laboratories, LLC. This action updates the ap…
-
FDA approval · 2008-10-30FDA Approved: RISPERIDONE — Original Application (Torrent Pharmaceuticals Limited)
FDA approves Torrent Pharmaceuticals Limited's original application for risperidone, providing a generic version of the antipsychotic.
-
CLINICAL_TRIALS trial_result · 2008-10-24Clinical Trial Update: Anti-Estrogens - A Potential Treatment for Bipolar Affective Disorder in Women? [Phase 2]
A Phase 2 trial of anti-estrogen therapy for bipolar affective disorder in women has completed, with related attention to mania and schizoaf…
-
FDA approval · 2008-10-16FDA Approved: RISPERIDONE — Original Application (Zydus Lifesciences Limited)
FDA approved an original abbreviated new drug application for risperidone by Zydus Lifesciences Limited, enabling the sale of a generic risp…
-
CLINICAL_TRIALS trial_result · 2008-10-07Clinical Trial Update: A Study in the Treatment of Acute Mania [Phase 4]
A Phase 4 trial in acute mania for bipolar disorder sponsored by Eli Lilly and Company was terminated. The document notes the trial status w…
-
CLINICAL_TRIALS trial_result · 2008-10-06Clinical Trial Update: Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder
This completed observational study evaluated whether use of atypical antipsychotics in a naturalistic setting improves quality of life for p…
-
CLINICAL_TRIALS trial_result · 2008-09-19Clinical Trial Update: A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain [Phase 2]
Phase 2 study evaluating the efficacy and safety of mifepristone to prevent olanzapine-induced weight gain has completed.
-
CLINICAL_TRIALS trial_result · 2008-09-19Clinical Trial Update: Open Label Trial of Acamprosate in Bipolar Alcoholics [Phase 1, Phase 2]
Open-label Phase 1/2 study evaluating acamprosate in individuals with alcohol dependence and bipolar disorder, completed.
-
FDA approval · 2008-09-08FDA Approved: LOXAPINE — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved a supplemental application from Actavis Pharma, Inc. for LOXAPINE (loxapine), establishing a generic loxapine product.
-
CLINICAL_TRIALS research · 2008-08-28Clinical Trial Update: To Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder. [NA]
This entry reports on a clinical trial sponsored by Shanghai Jiao Tong University School of Medicine to evaluate the efficacy and safety of …
-
CLINICAL_TRIALS trial_result · 2008-08-26Clinical Trial Update: Effects of Risperidone and Olanzapine on Patients With Schizophrenia, Schizoaffective Disorder, Major Depression or Bipolar Disorder [NA]
A completed clinical trial evaluating the effects of risperidone and olanzapine in patients with schizophrenia, schizoaffective disorder, ma…
-
FDA approval · 2008-08-14FDA Approved: ZYPREXA INTRAMUSCULAR — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Zyprexa Intramuscular (olanzapine), adding an intramuscular formulation to the product. This…
-
FDA approval · 2008-08-14FDA Approved: RISPERIDONE — Supplemental Application (Janssen Pharmaceutical, Inc.)
FDA approved a supplemental application for risperidone from Janssen Pharmaceuticals, updating the drug's labeling.
-
FDA approval · 2008-08-14FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
The FDA approved a supplemental application for Geodon (ziprasidone) submitted by Viatris Specialty LLC.
-
FDA approval · 2008-08-14FDA Approved: GEODON — Supplemental Application (Viatris Specialty LLC)
FDA approves a supplemental application for Geodon (ziprasidone mesylate) filed by Viatris Specialty LLC.
-
FDA label_change · 2008-08-11FDA Approved: SEROQUEL XR — Supplemental Application (AstraZeneca Pharmaceuticals LP)
FDA approved a supplemental application for SEROQUEL XR (quetiapine) submitted by AstraZeneca Pharmaceuticals LP. This approval results in l…
-
CLINICAL_TRIALS trial_result · 2008-08-07Clinical Trial Update: Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD [Phase 4]
This Phase 4 clinical trial update reports the completion of a study evaluating the combination of aripiprazole and methylphenidate in child…
-
CLINICAL_TRIALS trial_result · 2008-08-07Clinical Trial Update: Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD) [NA]
Clinical trial update on aripiprazole in children and adolescents with bipolar disorder and ADHD. The study status is completed.